Pasithea Therapeutics (KTTA) Projected to Post Quarterly Earnings on Thursday

Pasithea Therapeutics (NASDAQ:KTTA) is projected to release its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Pasithea Therapeutics to post earnings of ($0.16) per share and revenue of $0.30 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Pasithea Therapeutics (NASDAQ:KTTA) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.33. On average, analysts expect Pasithea Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pasithea Therapeutics Stock Down 6.5%

Pasithea Therapeutics stock opened at $0.47 on Tuesday. Pasithea Therapeutics has a twelve month low of $0.28 and a twelve month high of $2.06. The firm has a 50 day moving average price of $0.51 and a 200-day moving average price of $0.68. The company has a market capitalization of $15.84 million, a P/E ratio of -0.23 and a beta of 0.29.

Wall Street Analyst Weigh In

KTTA has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Pasithea Therapeutics in a research note on Tuesday, June 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Wednesday, June 24th. Finally, Zacks Research raised Pasithea Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $3.00.

Hedge Funds Weigh In On Pasithea Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of KTTA. Squadron Capital Management LLC purchased a new position in shares of Pasithea Therapeutics in the 4th quarter worth about $2,709,000. Janus Henderson Group PLC purchased a new stake in Pasithea Therapeutics during the 4th quarter valued at about $2,720,000. Adage Capital Partners GP L.L.C. bought a new stake in Pasithea Therapeutics during the 4th quarter valued at about $2,709,000. Vivo Capital LLC purchased a new position in Pasithea Therapeutics in the fourth quarter worth about $2,709,000. Finally, Persistent Asset Partners Ltd purchased a new position in Pasithea Therapeutics in the fourth quarter worth about $375,000. 23.92% of the stock is owned by institutional investors.

About Pasithea Therapeutics

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.